cyrilzakka/clinical-trials huggingface dataset:
Carpal Tunnel Syndrome - Randomized Clinical Trial Evaluating Effectiveness of Ultrasound in Corticosteroid Injection

The objective of this study is to evaluate the efficacy of ultrasound guided corticosteroid injection in reducing symptoms caused by carpal tunnel syndrome.

Corticosteroid injection is routinely given for treating carpal tunnel syndrome. The objective of this study is to evaluate the efficacy of ultrasound guided corticosteroid injection in reducing symptoms caused by carpal tunnel syndrome.

In this randomised clinical trial, 50 patients with both a clinical and electromyographic diagnosis of mild to moderate carpal tunnel syndrome will be recruited from the Centre Hospitalier Universitaire de Sherbrooke (CHUS). Subjects will be randomised to ultrasound guided or blind injection groups. All subjects will receive 40 mg of methylprednisolone. The primary outcome will be the Boston Carpal Tunnel Syndrome Questionnaire - Symptom Severity Scale at baseline and 3 months post injection. Both subjects and assessors will be blinded.

Eligibility Criteria:
Inclusion Criteria:

* Aged 18 to 65
* Understanding written and spoken french
* Diagnostic of carpal tunnel syndrome : Classic of probable based on the Katz Hand Diagram and mild to moderate based on the electrodiagnosis studies

Exclusion Criteria:

* Carpal tunnel injection in the last 6 months
* Constant symptoms in medial nerve area
* Thenar eminence atrophy
* Absolute contraindication to corticosteroid injection : infective arthritis, bacterial endocarditis, local cellulitis of skin infection, coagulopathy, corticosteroid or latex allergy
* Secondary diagnosis based on the ultrasound : arthrosynovial cyst, flexor tenosynovitis, ganglion
* Known cognitive disorder
* Anticoagulant therapy
* Diseases known to cause carpal tunnel syndrome : Diabetes mellitus, hypothyroidism, connective tissue disease, rheumatic disease and moderate or severe chronic renal impairment
* Radiculopathy
* Polyneuropathy
* Pregnancy
* Ancient ipsilateral wrist fracture
* Ancient ipsilateral wrist surgery
Tonsillar Retractor-induced Subacute Submassive Tongue Edema

This study aimed to detect tongue edema induced by the pressure exerted by tonsillar retractor; edema detection was made through tongue area measurement using ultrasonography (USG) in pediatric patients who underwent tonsillectomy surgeries.

The tongue is an ideal organ for ultrasonography (USG) evaluation. This study aimed to detect the occurrence of tongue edema through USG examination and to educate clinicians about the association between subacute tongue edema and tonsillar retractor in pediatric patients.

Eligibility Criteria:
Inclusion Criteria for study group:

* Patients aged 16 years or younger
* Undergo tonsillectomy surgery
* Patients informed consent obtained from the parents

Exclusion Criteria for study group:

* Patients aged older than 16 years
* Patients with a history of syndromal craniofacial abnormalities
* Patients with systemic disorders and other otolaryngologic problems

Inclusion Criteria for control group:

* Patients aged 16 years or younger
* Patients who did not need tonsillectomy surgery and any head and neck procedures
* Patients who underwent endotracheal intubation under general anesthesia except tonsillectomy and head and neck surgery.
Safety and Efficacy of Moxidex Otic

The purpose of this study is to determine if Moxidex otic solution is safe and effective in treating middle ear infections in patients with ear tubes.


Eligibility Criteria:
Inclusion Criteria:

* 6 months to 12 years of age
* Ear tubes in one or both ears
* Ear drainage visible by parent/guardian
* Ear drainage less than 21 days
* Other protocol-defined inclusion criteria may apply

Exclusion Criteria:

* Patients not otorrhea-free for 7 or less following tympanostomy tube surgery
* Ear tube with antimicrobial activity; ear tube longer than 2.5mm
* Non-tube otorrhea
* No otic surgery other than tube placement in the last year
* No menarchial females; no diabetic patients
* No patients with any disease or condition that would negatively affect the conduct of the study
* No patients taking any other systemic antimicrobial therapy during the study
* Patient must meet certain medication washouts to be eligible
* Analgesic use (other than acetaminophen) is not allowed
* Patients may not be predisposed to neurosensory hearing loss
* Other protocol-defined exclusion criteria may apply
Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor

In this study, the concentration of hemoglobin within the subject's blood is affected by fluid status changes. The fluid status is affected by fluid loss during surgery for hospitalized study subjects or controlled administration of fluids intravenously for healthy study volunteers. The accuracy of a noninvasive hemoglobin sensor(s) will be assessed by comparing with blood sample analysis.


Eligibility Criteria:
Inclusion Criteria:

* Has physical status between ASA 1 or 2
* Able to communicate in English

Exclusion Criteria:

* Pregnant or sexually active without birth control.
* Hemoglobin less than 11g/dL
* Known alcohol or drug abuse
* Skin abnormalities affecting the digits such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection
* Nail polish
* Head injury with loss of consciousness within the last year
* Known neurological and psychiatric conditions.
* Known concurrent chronic usage of psychoactive or anti-convulsive drugs within the last 90 days, or use in the last 7 days (i.e. tricyclic antidepressants, MAO inhibitors, lithium, neuroleptics, anxiolytics or antipsychotics. Except SSRIs
* Subject has any medical condition which, in the judgement of the investigator, renders them inappropriate for participation in this study, such as Reynods syndrome
* Hypertension: Systolic BP \>= 140 mmHg or Diastolic BP \>= 90 mmHg
* Baseline heart rate \<50 beats per minute
Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain

The purpose of this study is to determine whether coronary artery CT scanning or nuclear stress testing is better at diagnosing chest pain patients with coronary artery disease to select appropriate candidates for coronary catheterization and re-vascularization.


Eligibility Criteria:
Inclusion Criteria:

* patient admitted for chest pain or pressure
* patient at intermediate short term risk of MI or death (AHA/ACC guidelines)

Exclusion Criteria:

* prior diagnosis of coronary artery disease
* evidence of ongoing myocardial infarction (and other high risk criteria per AHA/ACC guidelines)
* contraindications to EKG-gated CT scanning with iodinated intravenous contrast under beta-blockade
* pregnancy
* presence of an implanted pacemaker or defibrillator
* stress myocardial perfusion imaging, coronary CTA or coronary catheterization within the last 6 months
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study

Current tests to detect cancer, including CAT scans and MRI scans, are limited. PET scans use special dyes that are injected into a vein and can better localize possible cancer. The investigators have developed a new particle that can carry a radioactive dye to a very specific area of the tumor. When using a PET scan the radioactive dye can be viewed in areas of possible disease. This particle has been studied in mice and was safe.

The particles will not treat the cancer and any images or information found during this study will not be used for your treatment. The information collected may be used to guide the design of future studies to detect and/or treat tumors.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Histologically confirmed diagnosis of melanoma or malignant brain tumor at MSKCC
* Newly-diagnosed or recurrent (local,regional, metastatic) metastatic melanoma or malignant brain tumor patients with
* Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas or malignant brain tumor
* Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region.
* Newly diagnosed patients with previous excisional biopsy.
* Normal baseline cardiac function based upon pre-operative evaluation
* At the discretion of the physician ANC\>1000/mcl and platelets\>100,000/mcl.
* At the discretion of the physician Bilirubin level of \< 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's).
* If patients have a history of malignancy other than melanoma or malignant brain tumor they must be disease-free (excluding primary cancer for metastatic patients) for ≥ 5 years at the time of enrollment.
* All patients of childbearing and child-creating age must be using an acceptable form of birth control
* Women who are pre-menopausal must have a negative serum pregnancy test

Exclusion Criteria:

* Abnormal thyroid function, such as untreated clinical diagnosis of hypothyroidism, hyperthyroidism, or other thyroid disease
* Known pregnancy or breast-feeding.
* Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer. This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.
* History of any malignancy (excluding primary cancer for metastatic patients) other than melanoma or malignant brain tumors for which the disease-free interval is \<5 years.
* Allergic reaction to iodine-containing contrast material
* Weight greater than the 400-lb weight limit of the PET scanner
* Claustrophobia
* Inability to lie in the scanner for 30 minutes
Pharmacokinetic Study: Effect of 25(OH)D and Vitamin D3 on Serum 25(OH)D

We compare the effect of HyD (25-hydroxyvitamin D) and vitamin D3 in their effect on 25-hydroxyvitamin D plasma levels over a course of 4 month. This is a pharmacokinetic study including 35 postmenopausal women.

* Trial with medicinal product

We include postmenopausal women age 50 to 75, race/ethnicity: Caucasian, serum 25(OH)D at baseline between 20 to 60 nmol/l, body mass index: \< 30 kg/m2

to compare 25(OH)D and vitamin D3 in equimolar doses over a 4 month pharmacokinetic trial. The dosing arms are daily, weekly, and bolus

Eligibility Criteria:
Inclusion criteria:

* Postmenopausal women
* Age 50 to 75 years
* Body mass index 18-29 kg/m2
* 25-hydroxyvitamin D levels 20 to 60 nmol/l
* Caucasian
* Generally healthy

Exclusion criteria:

* Serum calcium \> 2.6 nmol/L
* Use if dietary supplements (\> 400 IU vitamin D per day, \> 600 mg of calcium per day)
* Hypertension
* Diseases that carry the risk of hypercalcemia
* Use of any drug that interferes with bone metabolism in the last 12 months (bisphosphonates estrogen receptor modulators, PTH, calcitonin)
* Oral HRT in the last 6 months
* Extreme diets
* Fracture or fall in the last 3 months
* Current smoking or alcohol abuse
* Planning on a sunny vacation in the course of the trial
* Kidney stone history
* Creatinine clearance \< 30 ml/min
* Co-medications: anticoagulants, PTH, corticosteroids, thiazide diuretics, digoxin, anticonvulsants, malabsorption,z C
Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory

To investigate a computer-based Cognitive Remediation Therapy (CRT) for brain tumor patients at the Massey Cancer Center on measures of cognitive functioning (e.g., working memory, attention, processing speed, language, visuospatial functioning, immediate and delayed memory, or executive functioning) over time.

Participants will be recruited by their neuropsychologist in the VCU Massey Cancer Center following standard neuropsychological evaluation (their neuro-oncologist may refer them to this study). If meeting inclusion criteria (described in later sections on participants), participants will be recruited and enrolled in the study. Two groups will be formed: High grade gliomas (WHO grade III or IV; n=15) and Low grade gliomas (WHO grade II; n=15). Participants will be followed over 11 months. The two groups will follow identical study timelines.

Eligibility Criteria:
Inclusion Criteria:

* Confirmed primary brain tumor diagnosis via MRI and their neuro-oncologist
* A minimum of 2 months post-surgical resection or biopsy(if applicable)
* and/or a minimum 1 month post radiation treatment (if applicable)
* Karnofsky performance status more than 60
* Estimated intelligence at least 80 (standard score)
* Demonstrated attention difficulties (T-score of at least 65 on attention questionnaire or 1 or more standard deviations below mean on direct attention measures)
* No history of cognitive disorder
* No history of mood disorder
* Predicted life expectancy of at least 12 months
* Computer capability at home or provided a departmental iPad Mini to borrow for study purposes
* Primarily English speaking
* Aged 18+ (for which there is available age-adjusted neuropsychological testing standardization / normative data)

Exclusion Criteria:

* If they are not patients of Massey Cancer Center or do not meet the inclusion criteria listed above
Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes

Magnetic resonance (MR) imaging is a widely used and well-established noninvasive medical diagnostic imaging tool. By using a static and a gradient magnetic field in combination with a radiofrequency field (RF), MR provides excellent contrast among different tissues of the body. Although long-term effects on human health from exposure to strong static magnetic fields seem unlikely, acute effects such as vertigo, nausea, change in blood pressure, reversible arrhythmia, and neurobehavioural effects have been documented from occupational exposition to 1.5 T. Cardiac MR (CMR) imaging requires some of the strongest and fastest switching electromagnetic gradients available in MR exposing the patients to the highest administered energy levels accepted by the controlling authorities. Studies focusing on experimental teratogenic or carcinogenic effects of MR revealed conflicting results. Since CMR is emerging as one of the fastest growing new fields of broad MR application, it is of particular concern that a recent in vitro study with CMR sequences has reported on CMR-induced DNA damages in white blood cells up to 24 h after exposure to 1.5 T CMR. Therefore, we hypothesized that CMR can induce the damage of endothelium and endothelial progenitor cells in type 2 diabetes


Eligibility Criteria:
Inclusion Criteria:

* Male
* Age 30 to 65 years old
* Type 2 diabetes

Exclusion Criteria:

* Renal and liver function dysfunction
* Heart failure
* Malignancy
* Patients with contraindications to cardiac magnetic resonance (CMR)
* Patients with clinical detectable angiopathy
Impact of Non-pharmacological Prevention Measures on the Incidence of Delirium in Adult Intensive Care Units

The main objective is to evaluate the impact of the "bundle of actions" on the delirium's incidence in resuscitation patients during their stay in the service, compared to a conventional treatment.

The investigators therefore hypothesize that a set of coordinated paramedical actions in the prevention of delirium would reduce its incidence by 15% compared to conventional care.

The "Bundle of Actions" is a coordinated and specific action plan, which has already been validated, focusing on the coordination of wake-up and respiration, the management of delirium, as well as the early mobility of the patient. Innovation consists of simple, reproducible nursing care that reduces triggers of delirium; as well as the use of two new approaches in reanimation: conversational hypnosis and early and comprehensive re-empowerment of the patient in the management of his pain and well-being.

Eligibility Criteria:
Inclusion Criteria:

* Informed consent signed by the trusted person and the patient upon waking
* Hospitalized in reanimation service (first hospitalization or transfer of another service)
* 48 hours of sedation with intubation during hospitalization (all combinations of morphine, hypnotics, sedatives, anesthetics, narcoleptics)
* Francophone (able to understand all evaluations)

Criteria for the inclusion of 50 delirium positive patients drawn from the Toulouse center (participating in the neuropsychological evaluation): In addition to those mentioned above:

* Absence of pre-existing cognitive impairment (patients whose relative has completed the IQCode questionnaire and whose score is \<3.4 points)
* Visual, auditory (authorized equipment) skills and adequate oral or written expression for the proper conduct of neuropsychological tests.

Exclusion Criteria:

* Pregnant women
* Evolutive neurological disease leading to cognitive impairment (multiple sclerosis, Parkinson's disease, Alzheimer's disease), and / or focal neurological disease leading to cognitive impairment (head trauma, stroke, ...)
* Evolving psychiatric illness (including severe depression)
* Voluntary drug poisoning
* Patients who have already participated in the study
Concentrated Growth Factor Versus Platelet Rich Fibrin in Revitalization of Necrotic Young Permanent Incisors

Regenerative endodontic procedures (REPs) are the most recent proposal to manage immature permanent teeth with necrotic pulps. So in this study, the investigator will evaluate the clinical and radiographical revitalization success in necrotic young permanent anterior teeth of participants by using Concentrated Growth Factor versus Platelet-Rich Fibrin

has been entered

Eligibility Criteria:
Inclusion Criteria:

* Healthy patients with immature permanent incisors
* Presence of clinical signs and symptoms of necrosis or chronic apical periodontitis. The chronic apical periodontitis signs and symptoms include little discomfort with intermittent episodes of pus discharge through the sinus tract.

Exclusion Criteria

1. Abnormal tooth mobility.

* Positive history of allergic reaction, systemic diseases, severe emotional or behavioral problems.
* Unrestorable teeth
* Abnormal tooth mobility
* Children with systemic, severe behavioral, or emotional problems
Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders

The congenital absence of teeth, commonly referred to as hypodontia or tooth agenesis, is a common developmental anomaly of human dentition that affects approximately 20% of the population. Although new genetic and molecular approaches in humans and mice have increased our understanding of the molecules that control tooth patterning (number, position, shape and size), the precise nature of the genes involved in hypodontia in humans is poorly understood. Hence, understanding the molecular basis for missing teeth is an issue of paramount importance that is both timely and significant to the practice of dentistry. So far, only two genes have been associated with non-syndromic familial tooth agenesis: MSX1 and PAX9. Substitution mutations in the homeodomain region of MSX1 were linked to premolar agenesis while an insertion mutation in the paired box domain of PAX9 was shown to be responsible for molar oligodontia.

The long-term goals of this research are to elucidate the molecular pathology of human tooth agenesis, in particular, to evaluate whether genes other than MSX1 and PAX9 (locus heterogeneity) are involved. Alternatively, as in the case of MSX1, it will be interesting to know whether allelic variations, different mutations in these genes, are associated with tooth agenesis. We propose to study a potentially large kindred that report the developmental absence of several posterior teeth. The fundamental hypothesis to be tested states that the gene responsible for the congenital absence of molar teeth in this kindred is a critical element in the genesis of molars. The specific goals are to perform linkage analysis followed by direct sequencing of PCR products to identify the gene and to characterize the nature of the underlying defect. Identifying the underlying gene defect in this family affected by tooth agenesis will add new knowledge to our understanding of the pathogenesis of this defect and will provide the basis for future studies.


Eligibility Criteria:
* Patients affected with non-syndromic tooth agenesis and non-affected family members
Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS

Acute coronary syndrome (ACS) is any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). (1). In Egypt, the overall prevalence of coronary heart disease (CHD) is 8.3 % (2). In addition, CHD in Egypt is the principal cause of death, responsible for 21.73% of total mortality (2).

Beta-blockers have shown to reduce the short-term risk of a reinfarction and the long-term risk of all-cause mortality and cardiovascular mortality (3). Beta blockers are used within 24 hours of ACS and given as long-term therapy after discharge (4). The Most frequently used drug in Egypt is bisoprolol. In patients with myocardial infarction undergoing primary percutaneous coronary intervention, early intravenous betablocker before reperfusion reduced infarct size and increased left ventricular ejection fraction (4).drug interactions are common in ACS patients due to polypharmacy and comorbidities.(5) there are limited studies investigating drug interactions with bisoprolol in acute coronary syndrome patients. The proposed research in this application will investigate potential drug interactions with bisoprolol in patients with acute coronary syndrome.

1. Ethical committee approval will be obtained from Ethics committee of Faculty of Pharmacy, Damanhour University.
2. All participants should agree to take part in this clinical study and will provide informed consent.
3. Over 100 patients diagnosed with acute coronary syndrome for whom bisoprolol therapy is prescribed , will be recruited from Alexandria university hospital.
4. Blood samples for plasma concentration measurements of bisoprolol will be drawn at steady-state peak levels after 2-4 hours of administration of bisoprolol.

6. Heart rate and blood pressure of the patients will be measured to assess the clinical effect of bisoprolol.

Eligibility Criteria:
Inclusion Criteria:

1. Patients admitted with chest pain suspected to have ACS (acute coronary syndrome).
2. Both with ST elevation (STEMI) and without ST elevation (N-STEMI ) and unstable angina.
3. indicated to bisoprolol therapy

Exclusion Criteria:

Patients with contraindications to Bisoprolol therapy: